Analyst consensus rating
Novavax Analyst Rating: Buy
Direct answer
Novavax's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.22.
Forecast evidence checked October 17, 2026.
Get free Novavax email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $11.26
- Average price target
- $14.22
- High price target
- $25.00
- Low price target
- $7.00
- Low target gap
- -37.8%
- Target upside
- +26.3%
- High target gap
- +122%
- Target range width
- 159.9%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Novavax?
Novavax has a verified Buy consensus. The same dataset has an average price target of $14.22.
How far are Novavax's low and high targets from the recorded price?
The low target implies -37.8%, while the high target implies +122%.
How many analysts are included in Novavax's consensus?
The verified consensus includes 9 analysts.
How is Novavax's target upside or downside calculated?
The average target of $14.22 is divided by the recorded price of $11.26, then one is subtracted to produce +26.3%. This does not guarantee a future return.
When was Novavax's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.